ArticleKorean circulation journal2026
Long-Term Outcomes of Aspirin vs. Clopidogrel After PCI in High-Risk Patients With Cardiovascular Comorbidities: A Post Hoc Analysis of the HOST-EXAM Extended Trial.
Article in Korean circulation journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Consistency Matters: Clopidogrel Monotherapy as Long-term Secondary Prevention Following Percutaneous Coronary Intervention.Korean circulation journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
objectivesThe HOST-EXAM Extended trial demonstrated the long-term benefits of clopidogrel over aspirin monotherapy following dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). This sub-study evaluated these therapies in patients with and without previous cardiovascular disease (CVD).
methodsA total of 5,438 patients were randomized to aspirin (100 mg daily) or clopidogrel (75 mg daily) monotherapy. Previous CVD was defined as previous myocardial infarction, cerebrovascular accident, or peripheral artery disease, present in 1,137 patients; 4,301 had no CVD. The primary endpoint was a composite of all-cause death, non-fatal myocardial infarction, stroke, readmission due to ACS, and major bleeding (Bleeding Academic Research Consortium [BARC] type 3 or 5). Secondary endpoints included thrombotic and any bleeding events (BARC type ≥2). Median follow-up was 5.8 years.
resultsThe primary endpoint occurred more frequently in patients with previous CVD than in those without (18.1% vs. 13.7%, hazard ratio [HR], 1.045; 95% confidence interval [CI], 1.037-1.054; p<0.001). Regarding the treatment estimates for the primary endpoint between those with and without previous CVD, no significant interaction was observed (CVD group: HR, 0.784; 95% CI, 0.596-1.033 and non-CVD group: HR, 0.794; 95% CI, 0.675-0.934, respectively; interaction p=0.951). For thrombotic and bleeding composite endpoints, CIs were overlapping across CVD strata, indicating no clear heterogeneity.
conclusionsClopidogrel was associated with a lower risk of the primary endpoint versus aspirin after PCI, with no evidence of effect modification by previous CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.